DISCOUNT-ZERTIFIKAT - ASTRAZENECA | Market Closed - Deutsche Boerse AG 15:36:25 2024-05-17 EDT | ||
| 106.9 EUR | +0.01% |
|
| Current month | +0.40% | ||
| 1 month | +4.10% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 24-05-17 | 106.9 | +0.01% |
| 24-05-16 | 106.9 | +0.02% |
| 24-05-15 | 106.9 | -0.11% |
| 24-05-14 | 107 | 0.00% |
| 24-05-13 | 107 | +0.02% |
Delayed Quote Deutsche Boerse AG
Last update May 17, 2024 at 03:36 pm
More quotesStatic data
| Product type | Discount Certificates |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
Société Générale
|
| WKN | SU6Y3C |
| ISIN | DE000SU6Y3C0 |
| Date issued | 2024-01-15 |
| Maturity | 2024-09-20 (124 Days) |
| Parity | 1 : 1 |
| Emission price | 100.4 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 107.2 € |
|---|---|
| Lowest since issue | 92.44 € |
| Spread | 0.11 € |
| Spread % | 0.10% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
153.9
USD
Average target price
167.7
USD
Spread / Average Target
+9.02%
- Stock Market
- Certificates
- Certificat
